PT - JOURNAL ARTICLE AU - Samantha A. Natanek AU - Harry R. Gosker AU - Ilse G.M. Slot AU - Gemma S. Marsh AU - Nicholas S. Hopkinson AU - John Moxham AU - Paul R. Kemp AU - Annemie M.W.J. Schols AU - Michael I. Polkey TI - Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD AID - 10.1183/09031936.00098412 DP - 2013 Jun 01 TA - European Respiratory Journal PG - 1275--1283 VI - 41 IP - 6 4099 - http://erj.ersjournals.com/content/41/6/1275.short 4100 - http://erj.ersjournals.com/content/41/6/1275.full SO - Eur Respir J2013 Jun 01; 41 AB - Reduced quadriceps endurance in chronic obstructive pulmonary disease (COPD) is associated with a predominance of type II glycolytic fibres over type I oxidative fibres (fibre shift) and reduced muscle energy stores. The molecular mechanisms responsible for this remain unknown. We hypothesised that expression of known regulators of type I fibres and energy production in quadriceps muscle would differ in COPD patients with and without fibre shift. We measured lung function, physical activity, exercise performance, quadriceps strength and endurance (nonvolitionally) in 38 Global Initiative for Chronic Obstructive Lung Disease stage I–IV COPD patients and 23 healthy age-matched controls. Participants underwent a quadriceps biopsy: type I and II fibre proportions were determined using immunohistochemistry and fibre shift defined using published reference ranges. Calcineurin A, phosphorylated AMP kinase (phospho-AMPK)-α, protein kinase A-α catalytic subunits, modulators of calcineurin activity and calmodulin, 14-3-3 proteins were measured by Western blotting, and myocyte-enriched calcineurin-interacting protein-1 mRNA measured by quantitative PCR. Downstream, nuclear myocyte enhancer factor-2 capable of DNA binding was quantified by transcription factor ELISA. Unexpectedly, calcineurin expression was higher, while phospho-AMPK was lower, in COPD patients with fibre shift compared to COPD patients without fibre shift. Phospho-AMPK levels correlated with quadriceps endurance in patients. Reduced phospho-AMPK may contribute to reduced quadriceps oxidative capacity and endurance in COPD.